tbuckley/cabot-search huggingface dataset:
Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors
Authors: C. N. Sternberg, P. H. M. de Mulder, J. H. Schornagel, C. Theodore, S. D. Fossa, A. T. van Oosterom, F. Witjes, M. Spina, C. J. van Groeningen, C. de Balincourt, L. Collette
Journal: Journal of Clinical Oncology (2005)

4528 Background: This international randomized trial reports a 7.3 year update of an every 2 week regimen of high-dose-intensity chemotherapy with M-VAC plus G-CSF (HD M-VAC) compared to classic M-VAC (every 4 weeks) in patients (pts) with advanced transitional-cell carcinoma (TCC) (JCO 2001 May 15;19 (10):2638–46). Methods: 263 pts with TCC of the urinary tract (bladder, ureter, or renal pelvis), bidimensionally measurable distant metastases, no prior systemic cytotoxic or biologic treatment, and a WHO performance status of 0, or 1 were eligible. Treatment consisted of HD M-VAC: MTX 30mg/m2 d 1,VBL: 3mg/m2 d 2,ADM: 30mg/m2 d 2 and CDDP 70mg/m2 d 2 with G-CSF on d 3–7 in 134 pts vs. M-VAC: MTX 30mg/m2 d 1,VBL: 3mg/m2 d 2, ADM: 30mg/m2 d 2 and CDDP 70mg/m2 d 2 with MTX and VLB on d 15 and 22. in 129 pts. Using an intent-to-treat analysis, on the HD M-VAC arm there were 28 CRs (21%) and 55 PRs (41%), for an overall RR of 62% (95%CI 54% to 70%). On the M-VAC arm, there were 12 CRs (9%) and 53 PRs (41%), for an overall RR of 50% (95% CI, 42% to 59%). The p value for the difference in CR rate was .009; and for the overall response, was .06. Results: At a median follow-up of 7.3 years, 213 of 263 (81%) of patients have died. 24.6% are alive on the HD M-VAC arm vs. 13.2% on the M-VAC arm. By intent-to-treat analysis, median progression-free survival was better with HD M-VAC: 9.5 mos (95% CI 7.6–12.2) vs M-VAC 8.1 mos (95% CI 7.0–9.9). (p=.017; HR=0.73; 95% CI 0.56 - 0.95). The median survival was 15 mos and the mortality HR was 0.76 (95% CI: 0.58–0.99). The 2-year survival rate for HD M-VAC was 36.7% (28.3–45.0%) vs 26.2% for M-VAC (95% CI, 18.4%–34.0%). At 5 years, survival was 21.8% in the HD M-VAC arm (95% CI:14.5–29.2%) vs 13.5% (95% CI 7.4–19.6%).There was 1 toxic death in each arm; and more pts died to malignant disease in the M-VAC arm 76% vs 64.9% in the HD M-VAC arm. Conclusions: With longer follow-up, the initial results have been confirmed. HD M-VAC produces a borderline statistically significant relative reduction in the risk of progression and of the risk of death. No significant financial relationships to disclose.
Improved health outcomes are linked to higher social spending
Authors: Nigel Hawkes
Journal: BMJ (2016)

Countries with higher spending on social care have better health outcomes, a report published by the not for profit research organisation RAND Europe has shown.1

Spending on elderly people appears to have been particularly effective in improving population health, even for apparently unrelated outcomes such as infant mortality and low birth weight. Social spending funded by governments has a four times greater effect than privately funded spending, and as time passes the effects become more evident, possibly because it takes time for social spending to produce better health. Seven years or longer after social spending increases, its effects become more apparent.

The report’s main focus was …
Increase in T cells expressing the gamma/delta receptor and CD4+CD8+ double-positive T cells in primary immunodeficiency complicated by human T-cell lymphotropic virus type I infection [letter]
Authors: S Furukawa, K Sasai, J Matsubara, K Yabuta, K Hiramatsu, J Yamamoto, T Shirai, K Okumura
Journal: Blood (1992)
The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma
Authors: A.T. McConnell, R. Ellis, B. Pathy, R. Plummer, P.E. Lovat, G. O'Boyle
Journal: British Journal of Dermatology (2016)

Expression of the chemokine receptor CXCR4 is known to regulate melanoma metastasis to distant sites with high expression of the CXCL12 ligand. However, the prognostic impact of CXCR4 expression and potential for autocrine‐mediated activation of prosurvival mitogen‐activated protein kinase signalling remains enigmatic. Furthermore, expression of the decoy receptor CXCR7 within the local cutaneous melanoma microenvironment remains undefined. To define the contribution and prognostic impact of CXCR4–CXCR7–CXCL12 signalling in primary cutaneous melanomas and the immediate tumour microenvironment. Immunohistochemical/immunofluorescent expression of CXCR4, CXCR7 or CXC12 was analysed in human metastatic melanoma cell lines, primary cutaneous cell types and a retrospective cohort of primary melanomas/benign naevi. CXCL12 secretion by melanoma/cutaneous cells was evaluated by enzyme‐linked immunosorbent assay, and autocrine CXCR4–CXCL12 signalling was investigated by addition of a CXCL12‐neutralizing antibody. CXCR4 expression was significantly higher in primary melanomas that subsequently metastasized after 7 years (P = 0·037). Stratification for American Joint Committee on Cancer (AJCC) stage II disease revealed significantly decreased disease‐free survival in patients with > 50% CXCR4 expression (P = 0·036), while comparative analysis of CXCL12 expression in the adjacent epidermis of all AJCC stage melanomas revealed increased CXCL12 correlated with prolonged time to metastasis (P = 0·014). CXCR7 was expressed within the primary melanoma microenvironment but was absent on primary tumours. Addition of anti‐CXCL12 to BRAF‐mutant melanoma cells resulted in downregulation of phospho‐CXCR4 and phospho‐extracellular signal‐related kinase, indicating autocrine CXCR4–CXCL12 signalling. CXCR4 expression defines a potential prognostic biomarker for AJCC stage II melanoma. Moreover, targeting the CXCR4–CXCR7–CXCL12 axis may represent a novel therapeutic strategy to prevent early melanoma progression.
圧受容器反射不全は,駆出率正常心不全(HFpEF)の病因に関与している
Authors: Sakamoto Kazuo, Hosokawa Kazuya, Tobushi Tomoyuki, Onitsuka Ken, Fujino Takeo, Saku Keita, Kakino Takamori, Ikeda Masataka, Ide Tomomi, Sunagawa Kenji
Journal: Circulation (2013)
Attempt To Infect Nonmalignant Nasopharyngeal Epithelial Cells From Humans and Squirrel Monkeys With Epstein-Barr Virus&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: R Glaser, C M Lang, K J Lee, D E Schuller, D Jacobs, C McQuattie
Journal: JNCI Journal of the National Cancer Institute (1980)

With the use of Epstein-Barr virus (EBV), attempts were made to infect epithelial nasopharyngeal explant cell cultures prepared from nonmalignant human and squirrel monkey tissue. Explants were exposed to EBV from both HR-1 and B95-8 cells and examined for EBV-specific antigens by immunofluorescence and electron microscopy. Among the human specimens, no epithelial nasopharyngeal were found that could be infected with EBV. However, similar explants derived from squirrel monkey tissue were infected. The results were consistent with the hypothesis that EBV can infect at least certain explanted epithelial cells of the nasopharynx.
Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma (SWITCH-2 study).
Authors: Juergen Gschwend, Aart Beeker, Maria de Santis, Bernhard Brehmer, Matthias R. Zaiss, Silke Schirrmacher-Memmel, Ulla Von Verschuer, Monique M.E.M. Bos, Sascha Pahernik, Marc-Oliver Grimm, Steffen Krause, Margitta Retz
Journal: Journal of Clinical Oncology (2013)

TPS4591 Background: Sorafenib (SO) and pazopanib (PA) are both effective treatments for metastatic RCC (mRCC). For optimal treatment of mRCC patients (pts) it is essential to compare efficacy and safety of different sequential 1st and 2nd line treatments. The primary endpoint of this study is to evaluate if total PFS of SO followed by PA is non-inferior to PA followed by SO. Secondary objectives include time to progression during second-line treatment; time to first-line treatment failure in each arm, and PFS in first- and second-line treatment; overall survival; disease control rate in first- and second-line, safety and tolerability, and health-related quality of life. Also, a comprehensive translational research programme is integrated. Methods: Major inclusion criteria: pts with metastatic/advanced RCC not suitable for cytokines and for whom study medication constitutes first-line therapy; 18-85 years, ECOG PS 0 or 1, MSKCC score low or intermediate; at least one measurable lesion (RECIST 1.1). 544 pts will be randomized to the sequence SO→PA or PA→SO. Treatment under each drug continues until progression or intolerable toxicity. Between 1 st and 2 nd line therapy will be a treatment-free period of 1-4 wks. SO and PA are given in their registered doses. Pts undergo CT/MRI after every second cycle, i.e. after every 8 wks. The experimental arm will be considered to be non-inferior as long as the lower limit of the HR 95 % confidence interval (one-sided) excludes a median total PFS lower than 13.1 mos (=non inferiority margin). 383 events need to be observed to have 80% power to reject the null hypothesis of inferiority (HR ≥1.225) when the true HR=0.95. Recruitment started in June 2012. Study centers are in Germany, The Netherlands, and Austria. Clinical trial information: NCT01613846.
Phase I study of liposome irinotecan (PEP02) in combination with weekly infusion of 5-FU/LV in advanced solid tumors.
Authors: L. Chen, H. Shiah, T. Chao, R. K. Hsieh, G. Chen, J. Chang, G. Yeh
Journal: Journal of Clinical Oncology (2010)

e13024 Background: PEP02 is a novel nanoparticle liposome formulation of irinotecan (CPT-11) that has improved PK and tumor biodistribution of CPT-11 and its active metabolite-SN38 with encouraging safety and tumor response in preclinical studies and a single-agent phase I study. The study is to define the DLT, MTD, and PK of PEP02 when in combination with high-dose fluorouracil/leucovorin (HDFL) in patients (pt) with advanced solid tumors. Methods: Pts who had failed to standard chemotherapy, ECOG PS 0-1 and adequate organ functions, no prior CPT-11, were eligible. PEP02 was given as 90 mins i.v. infusion on D1 in combination with 24-hr infusion of 5FU (2,000 mg/m2)/ LV (200 mg/m2) on D1 and D8, every 3 weeks. Cohorts of 3-6 pts were treated at 60, 80, 100, and 120 mg/m2. PK and PGx samples were collected. Results: A total of 16 pts were enrolled, with 3, 6, 5, and 2 at 60, 80, 100, and 120 mg/m2. DLTs were observed in 4 pts, including 2 each at 100 and 120 mg/m2 dose levels. DLTs were mainly G3 diarrhea and G4 hematologic toxicities. MTD was determined as 80 mg/m2. Grade 3 or above adverse events at the MTD dose and all dose levels were 10.6% and 18.4%, respectively. The PK of total CPT-11 after PEP02 (at 80 mg/m2) in combination with HDFL was characterized by low clearance (mean = 116.4 mL/m2/hr) and small volume of distribution (mean = 2.93 L/m2, similar to plasma volume) as did of PEP02 monotherapy study. Compared to the PK of SN-38 after 250 mg/m2 of CPT-11 (in combination with capecitabine, Ann Oncol 2005; 16: 1123-32), the Cmax after 80 mg/m2 of PEP02 was lower (7.98 ± 4.39 vs 62.0 ± 37.4 ng/mL), but the AUC0→t was similar (354.77 ± 145.35 vs 396 ± 247 ng×h/mL). The correlation of UGT1A family with PK and toxicity was not observed. However, the only subject with the coexistence of two variants of UGT1A1*6 and *28 had higher dose-normalized AUCSN-38and experienced DLT. The best response of 15 evaluable pts was PR in 2 (gastric cancer and breast cancer) and SD in 9. Conclusions: The MTD of PEP02 in combination with HDFL given every-3-week is 80 mg/m2. The observation of tumor response in two heavily pre-treated patients suggests the combination deserves further exploration in advanced solid tumor patients who are refractory to standard therapy. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration PharmaEngine PharmaEngine PharmaEngine PharmaEngine
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy—Response
Authors: Francesca Vena, John A. Hartley, Daniel Hochhauser
Journal: Clinical Cancer Research (2016)

We thank the authors of this letter for their kind comments on our study and for their interesting discussion. However, we do not agree with the points made.

Point 1: “As stated by the Authors, KRAS mutations are detected in almost 90% of pancreatic ductal adenocarcinoma PDAC (3), supporting
Dermatologic Marvels—Hypertrichosis
Authors: Eric L. Maranda, David Fipps, Dagmara Danek, Richa Taneja, Amanda M. Marsh, Joaquin J. Jimenez
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
158P A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer; The HGCSG1401 study -first report
Authors: M. Dazai, S. Yuki, T. Muranaka, S. Yoshida, Y. Ohta, K. Hatanaka, Y. Tsuji, T. Ohta, A. Sato, K. Eto, K. Onodera, Y. Sato, K. Kato, M. Nakamura, O. Muto, A. Ishiguro, M. Tateyama, H. Okuda, Y. Sakata, Y. Komatsu
Journal: Annals of Oncology (2015)
The Footprint of Polygenic Adaptation on Stress-Responsive<i>Cis</i>-Regulatory Divergence in the<i>Arabidopsis Genus</i>
Authors: Fei He, Agustin L. Arce, Gregor Schmitz, Maarten Koornneef, Polina Novikova, Andreas Beyer, Juliette de Meaux
Journal: Molecular Biology and Evolution (2016)

Adaptation of a complex trait often requires the accumulation of many modifications to finely tune its underpinning molecular components to novel environmental requirements. The investigation of cis-acting regulatory modifications can be used to pinpoint molecular systems partaking in such complex adaptations. Here, we identify cis-acting modifications with the help of an interspecific crossing scheme designed to distinguish modifications derived in each of the two sister species, Arabidopsis halleri and A. lyrata. Allele-specific expression levels were assessed in three environmental conditions chosen to reflect interspecific ecological differences: cold exposure, dehydration, and standard conditions. The functions described by Gene Ontology categories enriched in cis-acting mutations are markedly different in A. halleri and A. lyrata, suggesting that polygenic adaptation reshaped distinct polygenic molecular functions in the two species. In the A. halleri lineage, an excess of cis-acting changes affecting metal transport and homeostasis was observed, confirming that the well-known heavy metal tolerance of this species is the result of polygenic selection. In A. lyrata, we find a marked excess of cis-acting changes among genes showing a transcriptional response to cold stress in the outgroup species A. thaliana. The adaptive relevance of these changes will have to be validated. We finally observed that polygenic molecular functions enriched in derived cis-acting changes are more constrained at the amino acid level. Using the distribution of cis-acting variation to tackle the polygenic basis of adaptation thus reveals the contribution of mutations of small effect to Darwinian adaptation.
Endobronchial ultrasound-guided transbronchial needle aspiration is feasible, safe, and reaches a 90 % diagnostic yield in patients with hypoxemic acute respiratory failure
Authors: Maxens Decavèle, Valérie Gounant, Jocelyne Fleury Feith, Michel Febvre, Jean-Marc Naccache, Antoine Parrot, Muriel Fartoukh
Journal: Intensive Care Medicine (2016)
Indoleamine 2,3-Dioxygenase-Expressing Aortic Plasmacytoid Dendritic Cells Protect against Atherosclerosis by Induction of Regulatory T Cells
Authors: Tae Jin Yun, Jun Seong Lee, Kawthar Machmach, Dahee Shim, Junhee Choi, Young Jin Wi, Hyung Seok Jang, In-Hyuk Jung, Kyeongdae Kim, Won Kee Yoon, Mohammad Alam Miah, Bin Li, Jinsam Chang, Mariana G. Bego, Tram N.Q. Pham, Jakob Loschko, Jörg Hermann Fritz, Anne B. Krug, Seung-Pyo Lee, Tibor Keler, Jean V. Guimond, Elie Haddad, Eric A. Cohen, Martin G. Sirois, Ismail El-Hamamsy, Marco Colonna, Goo Taeg Oh, Jae-Hoon Choi, Cheolho Cheong
Journal: Cell Metabolism (2016)
Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study
Authors: Alain Weill, Marie Dalichampt, Fanny Raguideau, Philippe Ricordeau, Pierre-Olivier Blotière, Jérémie Rudant, François Alla, Mahmoud Zureik
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To assess the risk of pulmonary embolism, ischaemic stroke, and myocardial infarction associated with combined oral contraceptives according to dose of oestrogen (ethinylestradiol) and progestogen. <b>Design</b>&nbsp;Observational cohort study. <b>Setting</b>&nbsp;Data from the French national health insurance database linked with data from the French national hospital discharge database. <b>Participants</b>&nbsp;4 945 088 women aged 15-49 years, living in France, with at least one reimbursement for oral contraceptives and no previous hospital admission for cancer, pulmonary embolism, ischaemic stroke, or myocardial infarction, between July 2010 and September 2012. <b>Main outcome measures</b>&nbsp;Relative and absolute risks of first pulmonary embolism, ischaemic stroke, and myocardial infarction. <b>Results</b>&nbsp;The cohort generated 5 443 916 women years of oral contraceptive use, and 3253 events were observed: 1800 pulmonary embolisms (33 per 100 000 women years), 1046 ischaemic strokes (19 per 100 000 women years), and 407 myocardial infarctions (7 per 100 000 women years). After adjustment for progestogen and risk factors, the relative risks for women using low dose oestrogen (20 µg <i>v</i> 30-40 µg) were 0.75 (95% confidence interval 0.67 to 0.85) for pulmonary embolism, 0.82 (0.70 to 0.96) for ischaemic stroke, and 0.56 (0.39 to 0.79) for myocardial infarction. After adjustment for oestrogen dose and risk factors, desogestrel and gestodene were associated with statistically significantly higher relative risks for pulmonary embolism (2.16, 1.93 to 2.41 and 1.63, 1.34 to 1.97, respectively) compared with levonorgestrel. Levonorgestrel combined with 20 µg oestrogen was associated with a statistically significantly lower risk than levonorgestrel with 30-40 µg oestrogen for each of the three serious adverse events. <b>Conclusions</b>&nbsp;For the same dose of oestrogen, desogestrel and gestodene were associated with statistically significantly higher risks of pulmonary embolism but not arterial thromboembolism compared with levonorgestrel. For the same type of progestogen, an oestrogen dose of 20 µg versus 30-40 µg was associated with lower risks of pulmonary embolism, ischaemic stroke, and myocardial infarction.
Commentary on Folkman: “How Is Blood Vessel Growth Regulated in Normal and Neoplastic Tissue?”
Authors: Hellmut G. Augustin
Journal: Cancer Research (2016)

Abstract Angiogenesis is a prerequisite for tumor growth and metastatic progression. The discovery of the first specific angiogenic cytokine, VEGF, in 1989 paved the way for the clinical approval of the first antiangiogenic tumor drug 15 years later. This brief commentary highlights and puts into historical perspective the 1985 G.H.A. Clowes Memorial Award Lecture delivered by Dr. Judah Folkman. Thirty years later, this award lecture is a lively testimony of the visionary mind of Dr. Folkman, whose legacy continues to inspire contemporary angiogenesis research. Cancer Res; 76(10); 2854–6. ©2016 AACR. See related article by Folkman J, Cancer Res 1986;46:467–73.
Garbanzo-Icchen-Cowardly-Pox
Authors: Jordan J. Cole, Eric L. Maranda, Tarek Salih, Scott F. Lindsey, Joaquin Jimenez
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Characteristics and Outcome Of Multiple Myeloma (MM) In African Americans (AA) Receiving Novel Agents and Autologous Stem Cell Transplantation (ASCT)
Authors: Vishal Bhatnagar, Yin Wu, Olga Goloubeva, Kathleen Ruehle, Todd Milliron, Saul Yanovich, Aaron P. Rapoport, Ashraf Badros
Journal: Blood (2013)
Abstract P336: Blood Pressure Responses to Cold Pressor Test and Incidence of Hypertension: The GenSalt Study
Authors: Jiang He, Qi Zhao, Lydia A Bazzano, Jing Chen, Jichun Chen, Jianfeng Huang, Jianxin Li, Jie Cao, Treva Rice, Katherine Mills, Chung-Shiuan Chen, Dongfeng Gu
Journal: Circulation (2013)

The cold pressor test (CPT), which measures the response of blood pressure (BP) to the stimulus of external cold, has long been a standard test to characterize sympathetic nervous system activity and has been documented to predict cardiovascular risk. We conducted a CPT among 1,998 Han Chinese in 2003-05 and followed the study participants in 2008-09 and 2011-12 for incidence of hypertension. CPT was conducted after the participant had remained sitting for 20 minutes. The participant immersed his or her left hand in the ice water bath (3°C to 5°C) for 1 minute and BP measurements at 0, 60, 120, and 240 seconds were obtained after the left hand had been removed from the ice water bath. During the follow-up examinations, 3 BP measurements were obtained on each of 3 clinical visits. The maximum and area-under-curve (AUC) of systolic BP responses (mean ± SD) to CPT were 13.9±10.2 and 17.1±22.9 at the baseline examination. Over an average of 7.4 years of follow-up, we identified 490 incidence hypertension cases (systolic BP≥140 mmHg and/or diastolic BP ≥90 mmHg and/or use of antihypertensive medication). The age-adjusted cumulative incidences of hypertension by the quartiles of systolic BP responses to CPT were showed in the following table. These associations remained after adjustment for multiple covariates. Our study identified a strong and independent association between BP responses to CPT and subsequent incidence of hypertension. These data suggest that increased sympathetic nervous system activity may play a role in the development of hypertension.